CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
急性髓系白血病治疗中 CAR-T 细胞分子靶点选择的问题
英文原题：The Problem of Molecular Target Choice for CAR-T Cells in Acute Myeloid Leukemia Therapy.
查看英文原题
The Problem of Molecular Target Choice for CAR-T Cells in Acute Myeloid Leukemia Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
最近，嵌合抗原受体（CAR）-T方法代表了B细胞恶性肿瘤治疗的突破，鼓励将该方法应用于其他血液疾病，如急性髓系白血病（AML）。病理细胞群体的异质性和抗原变异阻碍了AML分子靶点的选择。在这篇综述中，描述了在选择新CAR基因构建体的分子靶点时通常考虑的关键方面。涵盖了AML相关抗原在AML进展中的作用。总之，我们提出了一种可能更有效地消除AML病理细胞的方法。
展开英文摘要原文
Recently, the chimeric antigen receptor (CAR)-T approach represented a breakthrough in the treatment of B-cell malignancies, encouraging the application of the approach for other hematological diseases, such as acute myeloid leukemia (AML).
Heterogeneity and antigen variation in the pathological cell population hinder the choice of molecular targets in the case of AML. In this review, the critical aspects were described that are usually considered when selecting molecular targets for the new CAR genetic constructs. The role of AML-associated antigens in AML progression was covered.
In conclusion, we proposed an approach that may allow the elimination of pathological cells in AML more effectively.
论文信息
- 作者
- Maiorova V、Mollaev MD、Vikhreva P、Kibardin A、Maschan MA、Larin SS
- 单位
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow 117198, Russia.Russia
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2025 Jun 6
- 原文标识
- PubMed 40564892 · DOI 10.3390/ijms26125428
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →